Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | VCP | P55072 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | TGM2 | P21980 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | USP5 | P45974 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13439368 | 0.92 | KDM4E (0.41) | ALDH1A1L3MBTL1L3MBTL3PIM1SIGMAR1 | |
| SCHEMBL1106484 | 0.91 | ALDH1A1 (0.40) | ALDH1A1L3MBTL1L3MBTL3PIM1SIGMAR1 | |
| SCHEMBL11916119 | 0.89 | SIGMAR1 (0.37) | ALDH1A1L3MBTL1L3MBTL3SIGMAR1KDM4E | |
| SCHEMBL117945 | 0.89 | SIGMAR1 (0.41) | L3MBTL1L3MBTL3SIGMAR1 | |
| SCHEMBL18369768 | 0.88 | ALDH1A1 (0.32) | ALDH1A1L3MBTL1L3MBTL3PIM1 | |
| SCHEMBL14805853 | 0.88 | ALDH1A1 (0.32) | ALDH1A1L3MBTL1L3MBTL3PIM1 | |
| SCHEMBL13439372 | 0.84 | L3MBTL3 (0.42) | ALDH1A1L3MBTL1L3MBTL3SIGMAR1KDM4E | |
| SCHEMBL24960602 | 0.83 | ALDH1A1 (0.35) | ALDH1A1L3MBTL1L3MBTL3PIM1SIGMAR1 | |
| SCHEMBL12563384 | 0.82 | L3MBTL3 (0.39) | L3MBTL1L3MBTL3SIGMAR1HRH3 | |
| SCHEMBL1106434 | 0.82 | L3MBTL3 (0.43) | L3MBTL1L3MBTL3SIGMAR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399309-A1 | DEUTERATED HPK1 KINASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Guangzhou Yufan Nantu Biotechnologies Co., Ltd (CN) | 2023-12-14 | — | — | US | disclosed |
| US-11834454-B2 | Alkynylphenylbenzamide compounds and applications thereof | SHENZHEN NEWDEL BIOTECH CO., LTD. (CN) | 2023-12-05 | — | — | US | disclosed |
| US-11834454-B2 | Alkynylphenylbenzamide compounds and applications thereof | SHENZHEN NEWDEL BIOTECH CO., LTD. (CN) | 2023-12-05 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230348487-A1 | 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | GUANGZHOU SALUSTIER BIOSCIENCES CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230322822-A1 | ARYL PHOSPHOROUS OXIDE COMPOUNDS AND USE THEREOF | CHENGDU DI'AO JIUHONG PHARMACEUTICAL FACTORY (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230322822-A1 | ARYL PHOSPHOROUS OXIDE COMPOUNDS AND USE THEREOF | CHENGDU DI'AO JIUHONG PHARMACEUTICAL FACTORY (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230167099-A1 | NEW PYRAZINE COMPOUND | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230167099-A1 | NEW PYRAZINE COMPOUND | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20100317644-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20090298806-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-20090298806-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-7547694-B2 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-16 | — | — | US | disclosed |
| US-7521470-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20080188474-A1 | e.g. 1-phenyl-N3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-1H-1,2,4-triazole-3,5-diamine; receptor protein tyrosine kinase (AXL) antagonist; antiinflammatory, anticarcinogenic , antidiabetic agent; rheumatoid arthritis, vascular disease; breast, renal, endometrial, ovarian carcinoma, or myeloid leukemia | RIGEL PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080176853-A1 | e.g. N-(2-chloro-6-methylphenyl)-3-ethoxyacrylamide; protein (tyrosine and serine/threonine) kinase inhibitor; variety of conditions and diseases; antiproliferative, anticarcinogenic, antiinflammatory, antiallergenic agent; autoimmune and neurodegenerative disorders | ABRAXIS BIOSCIENCE, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080176853-A1 | e.g. N-(2-chloro-6-methylphenyl)-3-ethoxyacrylamide; protein (tyrosine and serine/threonine) kinase inhibitor; variety of conditions and diseases; antiproliferative, anticarcinogenic, antiinflammatory, antiallergenic agent; autoimmune and neurodegenerative disorders | ABRAXIS BIOSCIENCE, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080153815-A1 | PINANE-SUBSTITUTED PYRIMIDINEDIAMINE DERIVATIVES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | US | disclosed |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | ALDH1A1 3986/4885L3MBTL1 2955/4885L3MBTL3 3446/4885 |
| US-20230167099-A1 | NEW PYRAZINE COMPOUND | EGFR, ERBB2, WEE1 | ALDH1A1 2834/4885L3MBTL1 4516/4885L3MBTL3 4869/4885 |
| US-20230399309-A1 | DEUTERATED HPK1 KINASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, VRK1 | ALDH1A1 4110/4885L3MBTL1 2017/4885L3MBTL3 2734/4885 |
| US-20090298806-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | ALDH1A1 974/4885L3MBTL1 3511/4885L3MBTL3 4211/4885 |
| US-20100317644-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | ALDH1A1 1535/4885L3MBTL1 4648/4885L3MBTL3 4721/4885 |
| US-20230322822-A1 | ARYL PHOSPHOROUS OXIDE COMPOUNDS AND USE THEREOF | ALK, EGFR, ROS1 | ALDH1A1 2043/4885L3MBTL1 223/4885L3MBTL3 173/4885 |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | SULT2A1, STS, SULT1A1 | ALDH1A1 1535/4885L3MBTL1 4648/4885L3MBTL3 4721/4885 |
| US-11834454-B2 | Alkynylphenylbenzamide compounds and applications thereof | ALK, NTRK1, ERBB2 | ALDH1A1 972/4885L3MBTL1 2746/4885L3MBTL3 1943/4885 |
| US-20080153815-A1 | PINANE-SUBSTITUTED PYRIMIDINEDIAMINE DERIVATIVES USEFUL AS AXL INHIBITORS | AXL, TYRO3, MERTK | ALDH1A1 4120/4885L3MBTL1 3383/4885L3MBTL3 3873/4885 |
| US-20080176853-A1 | e.g. N-(2-chloro-6-methylphenyl)-3-ethoxyacrylamide; protein (tyrosine and serine/threonine) kinase inhibitor; variety of conditions and diseases; antiproliferative, anticarcinogenic, antiinflammatory, antiallergenic agent; autoimmune and neurodegenerative disorders | MAP3K15, DSTYK, STK25 | ALDH1A1 4099/4885L3MBTL1 1767/4885L3MBTL3 1929/4885 |
| US-20230348487-A1 | 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | JAK3, JAK2, JAK1 | ALDH1A1 2774/4885L3MBTL1 3047/4885L3MBTL3 859/4885 |
| US-20080188474-A1 | e.g. 1-phenyl-N3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-1H-1,2,4-triazole-3,5-diamine; receptor protein tyrosine kinase (AXL) antagonist; antiinflammatory, anticarcinogenic , antidiabetic agent; rheumatoid arthritis, vascular disease; breast, renal, endometrial, ovarian carcinoma, or myeloid leukemia | AXL, TYRO3, FLT3 | ALDH1A1 2732/4885L3MBTL1 2249/4885L3MBTL3 2209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.